A New Day Begins With SPRAVATO
The first and only NMDA receptor antagonist approved for TRD in adults
SPRAVATO™ hypothesized mechanism of action
SPRAVATO™ clinical program overview
BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS1,2
COMPARED TO PLACEBO NASAL SPRAY + ORAL AD1
1.SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2019.
2.Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.
SPRAVATO™ (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.
SPRAVATO™ is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO™ as an anesthetic agent have not been established.